Compare Adaptive Biotechnologies Corp (ADPT) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs D R Horton Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.45 (market cap $4.02B), while D R Horton Inc trades at $149.8 (market cap $40.79B). The key difference: D R Horton Inc is far larger — about 10.1× Adaptive Biotechnologies Corp's market cap, and D R Horton Inc pays a 1.23% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DHI | |
|---|---|---|
Market Cap | $4.02B | $40.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $184.04 |
52-Week Low | $12.30 | $132.53 |
Enterprise Value | $4.08B | $45.89B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.
Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.
DHI trades at $149.88, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral RSI. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year guidance amid weak homebuying demand. Valuation metrics appear reasonable with a P/E of 13.9 and P/S of 1.27. Recent news highlights management's focus on cost control and inventory discipline to offset market challenges.
The outlook is mixed; strong cash flow and execution provide support, but elevated mortgage rates and sluggish demand pose headwinds. Analyst consensus leans neutral with a $153 price target. Key risks include margin pressure and macroeconomic sensitivity, while the dividend offers income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
